Although not explicitly marketed as a weight loss medication, studies funded by Novo Nordisk, the manufacturer of Ozempic, suggest that individuals taking semaglutidethe active ingredientmay experience weight loss
Patent No.10,278,923 describes the use of GLP-1 peptides in oral therapy
Improving insulin sensitivity helps prevent the storage of excess fat and ensures that the body is better able to process and use glucose for energy rather than storing it as fat
Sustained Appetite Control : It works well for people who need long-term help managing their appetite and cravings
In this case, they stimulate aryl hydrocarbon receptors, which encourage your body to produce more glucagon, the precursor to GLP-1
Meanwhile, CagriSema was associated with increased rates of GI adverse effects and mild hypoglycemia